62124-77-0

Basic information

• Product Name: ETHYL 3-OXO-3-PYRAZIN-2-YL-PROPIONATE
• Synonyms: ETHYL 3-OXO-3-PYRAZIN-2-YL-PROPIONATE;ethyl beta-oxopyrazinepropionate;β-Oxo-2-pyrazinepropionic acid ethyl ester;Ethyl 3-(2-Pyrazinyl)-3-oxopropanoate;Ethyl 3-oxo-3-(pyrazin-2-yl)propanoate;2-Pyrazinepropanoic acid, beta-oxo-, ethyl ester;beta-Oxo-2-pyrazinepropanoic acid ethyl ester;Ethyl 3-oxo-3-pyrazinylpropionate
• CAS NO: 62124-77-0
• Molecular Formula: C₉H₁₀N₂O₃
• Molecular Weight: 194.19
• EINECS: 263-421-0
• Mol File: 62124-77-0.mol
• Article Data: 11

Chemical Properties

• Melting Point: 61.0 to 65.0 °C
• Boiling Point: 120°C/2mmHg(lit.)
• Appearance: /
• CAS DataBase Reference: ETHYL 3-OXO-3-PYRAZIN-2-YL-PROPIONATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-OXO-3-PYRAZIN-2-YL-PROPIONATE(62124-77-0)
• EPA Substance Registry System: ETHYL 3-OXO-3-PYRAZIN-2-YL-PROPIONATE(62124-77-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 62124-77-0(Hazardous Substances Data)

Usage

General Description

ETHYL 3-OXO-3-PYRAZIN-2-YL-PROPIONATE is a chemical compound with the molecular formula C10H12N2O3. It is a pyrazine derivative that is commonly used as a flavoring agent in the food and beverage industry. It has a fruity and popcorn-like aroma, making it a popular choice for enhancing the flavor of various food products. Additionally, it is also used in the pharmaceutical industry as an intermediate in the synthesis of other compounds. However, it is important to note that this chemical should be handled with care, as it may pose health risks if not used properly.

Upstream product

• 98-97-5 2-pyrazylcarboxylic acid 
• 1071-46-1 hydrogen ethyl malonate 
• 141-78-6 ethyl acetate 
• 6924-68-1 ethyl 2-pyrazinecarboxylate 
• 19847-10-0 pyrazinoyl chloride 
• 105-53-3 diethyl malonate 
• 6164-79-0 methyl pyrazine-2-carboxylate 
• 22047-25-2 acetylpyrazine 
• 105-58-8 Diethyl carbonate 

Downstream Products

• 64223-90-1 ethyl 2-methyl-3-oxo-3-(pyrazin-2-yl)propanoate 
• 64224-21-1 Oltipraz 

Relevant articles and documents

Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099)

AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.

2- (PIPERIDIN-1-YL) -4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS

Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described. Ring A is selected from formula (a), (b) or (b'):

Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists

Compounds having the structural formula I are disclosed, wherein A is alkylene, or optionally substituted arylene, cycloalkylene or heteroaryldiyl; X is —C(O)— or —S(O)2—; R1 is alkyl or cycloalkyl; R2 is hydrogen, halo or —CN; R3 is hydrogen or alkyl; R4 is hydrogen, alkyl, alkoxy, hydroxyalkyl, aminoalkyl-, cycloalkyl, heterocycloalkyl, heterocycloalkyl substituted by alkyl, optionally substituted arylalkyl or optionally substituted heteroarylalkyl; or R3 and R4, form an optionally substituted 5-7 membered ring, said ring optionally comprising an additional heteroatom ring member; R7 is alkyl, optionally substituted phenyl, optionally substituted heteroaryl, cycloalkyl, halo, morpholinyl, optionally substituted piperazinyl, or optionally substituted azacycloalkyl. Also disclosed is the use of the compounds in the treatment of Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, pharmaceutical compositions comprising them and kits comprising the components of the combinations.